Section Arrow
Quote
FDMT.NASDAQ
- 4D Molecular Therapeutics
Quotes are at least 15-min delayed:2026/10/18 21:41 EDT
Regular Hours
Last
 12.14
-0.73 (-5.67%)
Day High 
12.84 
Prev. Close
12.87 
1-M High
16.23 
Volume 
794.54K 
Bid
9.7
Ask
12.3
Day Low
12 
Open
12.84 
1-M Low
11.99 
Market Cap 
710.99M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.82 
20-SMA 13.8 
50-SMA 13.88 
52-W High 16.93 
52-W Low 6.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.63/-4.42
Enterprise Value
726.81M
Balance Sheet
Book Value Per Share
7.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
85.21M
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.